RARE Ultragenyx Pharmaceutical Inc

$RARE patience its going to go higher $PDSB patience its going to go higher Theyneverlisten patience we will print more

RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results $RARE $XBI $VTI https://stocktwits.com/news/equity/markets/rare-stock-climbs-this-week-as-investors-look-past-trial-failure-to-gene-therapy-launches-trial-results/cZMPUIGRB7Q

$RARE $RARE now combines 6 approved therapies, 2026 revenue guidance of $730–760M that excludes the new launches, two newly commercialized gene therapies, and a major cost reduction plan targeting profitability in 2027 — meaning revenue growth and margin expansion could happen at the same time, a rare combination for a company of this size.

$RARE $RARE is officially in an uptrend. We've left all the noise, doubts, and negativity behind—confidence and conviction are back in full force. Next target is $18, then we break through the $20 resistance, paving the way for a run straight to $30. Why rush to sell when your money is actively compounding and growing? Stay calm and enjoy your life while you watch your wealth continuously multiply.

$RARE $CAPR whole bio market getting crushed for no reason following XBI. Stop crying and take the opp to buy if you can

$RARE It has bottomed at 14 and is posed for recovery - multi-drug companies with portfolio of FDA-approved drugs and extensive pipeline like the one RARE has - they always move on even after setbacks like the one with Angelman. September is always the weakest month for stocks, and also add the geopolitical and macro noise from oil prices and bond yields soaring.

$RARE $RARE is seeing unusually heavy trading, and the reasons are clear. Takeover speculation has increased after Novo Nordisk’s CEO said the company is ready to pursue larger M&A, while investors are also starting to understand the scale of RARE’s two recent approvals. There is still no confirmed deal talk. FAYUVI is priced at $3.95M per patient and GENGLYCOS at $2.7M. RARE also had about $436M in cash at the end of Q2, plus 2 PRVs potentially worth roughly $360–410M combined. The pipeline still includes DTX301 in Phase 3, targeting a market of roughly 10,000 patients, with a key 2027 readout ahead. Meanwhile, management is guiding to $730–760M in 2026 revenue and had already targeted profitability in 2027 before the two newest launches began contributing meaningfully. Six approved therapies, two new gene therapies, 2 PRVs, $436M cash, a Phase 3 asset, and only about a $1.4B market cap — this is why the market is starting to reprice RARE.

$RARE making money is great but this company is also saving people's lives by treating diseases nobody else is even trying to cure The government should guarantee every kid who needs these treatments get it one way or another... or we can just send more bombs to Israel while they provide their own citizens with universal healthcare.

$RARE RARE could easily gap toward $18–$20, depending on what the two PRVs ultimately sell for. But if there’s still NO PRV sale announcement soon, that gets even more interesting. My theory is that a Big Pharma could be negotiating to acquire the entire company and take both valuable PRVs as part of the package. With RARE’s approved products, pipeline, and two PRVs, I believe a $30–$35 buyout is very possible. Something may be happening behind the scenes.

$RARE Ultragenyx, a rare-disease drugmaker, will keep about $168M, not $210M, from selling its FDA priority review voucher: its 8-K says 20% of the gross goes to the NIH under a 2018 license. That is non-dilutive cash worth about 1.7 quarters of operating burn ($97M in Q2), on top of $436M held at June 30. The company says it supports its path to profitability in 2027. Against that: it is a one-time sale, not recurring revenue. Closing waits on an antitrust review.

When $RARE takes off I think I’m going to buy a 1969 Trans Am & start doing cocaine again.

$RARE Based on a conservative valuation model of their active commercial revenue, immediate voucher cash, and new product launches, Ultragenyx's fair value should realistically sit between $2.78 billion and $3.57 billion. This implies a fair value stock price range of $28.20 to $36.20 per share, representing a 95% to 150% upside from its current depressed price of ~$14.50.

$RARE The all-time high trading price for Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) was $179.65, reached on December 23, 2020. And you're waiting for the stock to drop to $14 to buy more? If you don't see current price as a buying opportunity then you're counting your pennies.

$RARE Is it possible that RARE share price closes green today? I've seen it happen many times. The chart does not lie we're moving up!

$RARE - At around $15, RARE offers an attractive long-term risk/reward because the market has already heavily discounted the GTX-102 setback, while the company still has a growing commercial business led by Crysvita. The recent approvals of FAYUVI and GENGLYCOS, combined with a pipeline including DTX301 and UX701, provide multiple potential growth drivers over the next several years. If Ultragenyx executes well and reaches profitability as planned, the current valuation could prove significantly undervalued. Disclouse - I am an longterm Investor with 10K share with an average price of $20.56

$RARE this isnt real. No one is selling shares for $14.35. We simply are witnessing short sellers who are stuck and dont want to cover yet.

$RARE A slight intra-day pause to form the left shoulder of a reverse H&S and then off to the races to $20+ by next week.

$RARE 👈ridiculously low price…. Loading here again. Chart. Massive pipeline. Way undervalued. They will find it.

$RARE was literally $26 not even a month ago…no reason so be this low with all the approvals

$RARE I called this at 14.6, at 14.8 and told everyone it had a gap up to 20. It’s time, you’re still on time, buy now